GLP-1 medications have ushered in a new era in weight loss. In just a few years, drugs like semaglutide and tirzepatide, known by the brand names Ozempic, Wegovy, Mounjaro, and Zepbound, have transitioned from niche treatments for diabetes to household names, reshaping how Americans think about losing weight. This shift highlights the growing require for comprehensive strategies to manage weight and maintain long-term health.
- High-quality protein for people over 50: 3 easy sources to include in your diet
- Flávia Bacelar: what is multiple organ failure, cause of death of the 31-year-old journalist
A Kaiser Family Foundation survey conducted in November 2025 revealed that 1 in 8 adults in the U.S. Has tried a GLP-1 medication for weight loss, diabetes, or another condition.
The ability of these medications to aid patients lose between 15% and 20% of their body weight has made them one of the most effective non-surgical treatments ever seen for obesity.
GLP-1, short for glucagon-like peptide-1, is a hormone naturally produced by the gut that helps regulate blood sugar and appetite after meals. It signals the pancreas to release insulin when blood sugar levels rise and slows down the rate at which food leaves the stomach, which helps people feel full more quickly.
Modern GLP-1 medications are designed to amplify these effects, leading to improved blood sugar control and substantial weight loss for many patients.
But success brings a new question that millions of people are facing: what happens after the weight is lost? And, equally important, what should patients do when their progress suddenly plateaus, even while still taking the medication?
- Favors bone protection: locate out which food can help increase muscle mass when included in your diet
As a physician specializing in obesity, I have witnessed firsthand the transformative impact that GLP-1 medication therapy can have on my patients’ lives. But I similarly remind each of them that no medication—including GLP-1s—replaces the fundamental importance of nutrition, physical activity, sleep, and mental health. These lifestyle pillars are essential for maintaining muscle and bone health, preventing significant weight regain, and promoting long-term cardiovascular and metabolic health.
The key is simple, but crucial: every weight loss or health plan should be personalized to each individual.
How the Body Reacts to Weight Loss
In 2023, the Centers for Disease Control and Prevention (CDC) reported that more than 40% of American adults live with obesity. For most people, the real challenge isn’t losing weight, but keeping it off.
Researchers have known this for decades. As early as the mid-20th century, studies on commercial weight loss programs showed that while short-term weight loss was common, long-term weight regain was the norm.
This represents because, when people lose weight, the body’s natural tendency is to return to its previous weight—a phenomenon called metabolic adaptation. The brain releases more ghrelin, the hunger hormone, and decreases leptin, one of the hormones that signals fullness and sufficient energy.
The bottom line is simple: after weight loss, people feel hungrier, less full after meals, and burn fewer calories than expected. The body interprets weight loss as a threat to survival and responds by slowing metabolism through sophisticated energy-conservation mechanisms. In other words, when there is less body weight to maintain, the body works less—but also becomes more efficient, burning fewer calories than predicted and causing the weight to creep back on.
Add to that an environment filled with ultra-processed foods, oversized portions, high stress levels, and little time for exercise, and it’s no surprise that so many people’s weight fluctuates despite their best efforts.
Putting GLP-1 Medications to the Test
Clinical trials with GLP-1 medications also follow these well-established patterns. A pivotal clinical study from 2021 with more than 1,900 adults, known as the STEP 1 study, laid the groundwork for the use of these medications as a treatment for weight loss.
But a follow-up study from 2021, known as STEP 4, showed that 48 weeks after stopping semaglutide, participants regained approximately two-thirds of their previous weight loss, while those who remained on GLP-1 medication therapy continued to lose weight.
This isn’t because people lack discipline, but rather because their biology fights hard to return to its previous set point.
Lower Cost and Longer Duration Maintenance
While obesity is now widely recognized as a chronic disease, clinical guidelines haven’t fully caught up with this new generation of highly effective medications.
For most patients, the most effective long-term strategy after reaching their desired weight is to continue GLP-1 treatment. Physicians aim for the lowest dose that still helps regulate appetite and stabilize weight.
Another option patients can consider is a gradual reduction of medication over three to six months, focusing on reinforcing lifestyle choices that support overall health goals and weight maintenance.
When Your Weight Stalls on a GLP-1 Medication
Plateaus in weight loss are normal, even with GLP-1 medications.
In clinical trials, weight loss with GLP-1 medications tends to follow a predictable curve: rapid losses early in treatment and during dose escalation, a gradual slowing, and eventual stabilization. A stabilization, typically defined as little or no change in weight for eight to twelve weeks, isn’t a sign of failure, but rather the body adapting to a lower weight.
But before assuming a GLP-1 medication has stopped working, doctors typically consider how the patient is using the medication, for example, whether it’s being taken correctly, with few or no missed doses, and whether it’s being stored properly.
Doctors will also assess whether the patient has medical conditions that may be hindering weight loss, such as perimenopause or hypothyroidism, which is the underactive function of the thyroid.
They will also consider whether the patient is taking other medications that may be obesogenic—that is, cause weight gain—or whether they are using an FDA-approved medication instead of a compounded medication, which may have variable quality and unknown efficacy.
Balancing Weight Loss with Bone Health
Helpful strategies for preventing weight-regain related to diet include meal planning around lean proteins and noting where calories may be accumulating, such as in snacks, sugary drinks, and alcohol.
With GLP-1 medications, the focus of nutrition has shifted from calorie restriction to the quality of calories. Seek a healthy balance of vegetables, lean proteins, and whole grains. And be sure to drink enough water, especially because GLP-1 medications not only reduce hunger but can also decrease the sensation of thirst.
Sparkling water: the surprising benefits of the drink for the organism
Regarding movement and exercise, people can add resistance training, increase the intensity of exercise, or both.
With any weight loss, regardless of the method, people lose not only fat but also muscle and bone mass. In clinical trials with GLP-1 medications, fat loss far outweighs lean mass loss. However, any loss of lean mass is important, as it can affect physical function, fracture risk, and the body’s ability to maintain weight and metabolic health over time.
Weight loss reduces the mechanical load on bones, which can lead to decreased bone density and, in some people—such as postmenopausal women and those over 65—an increased risk of fractures. Because bones adapt to the weight they bear, losing weight means less stress on the skeleton and, over time, this can lead to small reductions in bone strength. This reinforces the importance of resistance exercise for muscle strengthening, adequate protein intake during GLP-1 therapy, and close monitoring of patients at higher risk of fractures.
Next-generation therapies, including combinations of GLP-1 medications and other peptides, are being studied for their potential to better preserve muscle and bone compared to GLP-1 medications alone.
Patients using GLP-1 medications who are experiencing stabilization of results can talk to their doctor about the possibility of dose adjustment, medication change, or addition of a complementary medication.
If GLP-1 medication doses cannot be increased due to side effects, doctors will consider all options of other medications and optimization of lifestyle, such as nutrition, exercise, and sleep, to support the patient’s goals.
*Amy J. Sheer is an associate professor of Medicine at the University of Florida
